Monsenso is proud to announce a new working partnership with UK’s telecare provider, Centra. The joint work will explore new, digital approaches to mental health service provision at Amy’s Place’ – Centra’s and Amy Winehouse Foundation’s (AWF) flagship addiction recovery service in East London.
The Monsenso mHealth app offers a comprehensive solution for managing a range of affective disorders, including depression, bipolar disorder, schizophrenia and borderline personality disorder. By utilising everyday smartphone technology, Monsenso supports individuals to self-manage their conditions whilst providing valuable insights to their mental health or social care support worker.
The Monsenso solution combines self-reported data and environmental sensor data to provide a balanced view of an individual’s behaviour and mood over time. The data can be accessed by nominated support staff to help inform diagnosis and treatment pathways.
Over the past ten months Centra’s Research and Innovation (R&I) team has worked closely with Monsenso as well as staff and residents at Amy’s Place to evaluate and configure the solution.
A pilot program will be established for six months, with testing conducted by a group of young women currently living at Amy’s Place and their support workers. Throughout the pilot, the service will be evaluated and supported by Centra’s R&I team to ensure that it meets expectations and maximises its benefits..
Centra is one of UK’s largest providers of telecare services delivering a range of life-saving alarm and monitoring services to social care workers, housing associations, health professionals, local authorities and individuals. Supporting over 100,000 customers across the country, our aim is to help people live safely and independently for longer. Our in-house Telecare team provide 24/7 call monitoring and support our clients with wellbeing checks, automated “I’m OK” calls and scheduled medication reminders. We also offer GPS-enabled devices for round-the-clock support away from home. As industry leaders, we provide cutting-edge technology solutions and tailored support that help meet customers’ ever-changing needs. To learn more, visit www.centragroup.org.uk
Monsenso is an innovative technology company offering a mHealth solution that optimises the treatment of mental disorders. Our mission is to help individuals, carers, healthcare providers and researchers overcome the burden of mental illness. Our solution provides a detailed overview of an individual’s mental health through the collection of behavioural data and self-monitoring, and by connecting individuals, carers and health care providers it supports self-care, informal care as well as formal treatment. Based on continued research and development, our team is committed to developing comprehensive solutions that fit seamlessly into the lives of individuals, increasing the quality and efficacy of their mental health and treatment. To learn more, visit www.monsenso.com
About the Amy Winehouse Foundation
The Amy Winehouse Foundation works to prevent the effects of drug and alcohol misuse on young people. We also aim to support, inform and inspire vulnerable and disadvantaged young people to help them reach their full potential. We are driven by a powerful vision for young people, a world where young people can flourish. To learn more, visit www.amywinehousefoundation.org
Developing our QMS is a continuous process. Recently, Monsenso has upgraded its QMS to the latest version of the standard EN ISO 13485 to the new revision: DS/EN ISO 13485:2016. Monsenso was audited by Bureau Veritas Certification Denmark A/S in June 2018 and found to be following the established procedures and the requirements of the standard DS/EN ISO 13485:2016.
So, what has Monsenso implemented in QMS to reflect the new standard and how does this affect users?
Quality management system with expanded risk management approach
According to the new version of the ISO standard, a risk based approach needs to be implemented in all the processes connected with the manufacturing of the medical device. This approach also include Monsenso’s suppliers.
In order to accommodate for this risk-based approach, Monsenso has implemented an extra layer of data security to our existing processes. This ensures that the evaluation / monitoring of our suppliers is proportionate to the risk associated with the purchased product. Monsenso’s critical suppliers are now placed on a risk level from I-IV, this ranking reflects the importance of the provided product relative to the medical device.
This implementation has helped to strengthen the control process of the suppliers, and helps to reduce risks that could potentially affect our customers and users of the product.
Closer to compliance with the requirements of the US market
Additionally, the new update of EN ISO 13845:2016 is in more alignment with US legislation and standards (FDA 21 CFR Part 820). Therefore, Monsenso is closer to meeting regulatory requirements of the FDA. FDA was a contributor to the new version and a lot of its regulation requirements are covered by this revision.
By upgrading their quality and security standards to become compliant with EN ISO 13845:2016, Monsenso has obtained an improved position to be aligned with worldwide requirements, including future compliance with FDA requirements on the US market.
Annual audit of ISO 27001 Information Security Management System
At the same time, Monsenso went through annual audition of ISO 27001. Compliance with this certification validates that Monsenso’s comprehensive information security practices protect its users and their information in accordance with internationally recognised standards.
The ISO 27001 standard ensures the secure management of customers’ information, intellectual property, and third party information by establishing methodologies and meeting key objectives for implementing information security.
For fire år siden blev jeg diagnosticeret med bipolar lidelse type 2.
I hele mit liv har jeg vidst, at jeg var anderledes. Jeg har altid kæmpet med depression og angst, og hvad der viste sig at være hypomani. Da jeg var 22, havde jeg min første slemme depressive episode, og jeg blev nødt til at starte på antidepressiver. Alligevel tog det yderligere 6 år, før jeg officielt blev diagnosticeret med bipolar lidelse type 2.
Det sværeste, ved at have diagnosen bipolar lidelse type 2, er at man ikke oplever den typiske maniske episode, hvor man er over-energisk og på grænsen til psykotisk. I stedet er man hypomanisk, som betyder at man er socialt velfungerende. Man er ikke psykotisk. Man føler sig faktisk rigtig godt tilpas. Så problemet er, at man ikke ender med at tage til sin psykiater og sige, at man føler sig for godt tilpas. Det gjorde jeg i hvert fald ikke!
Årsagen til at min psykiater fandt ud af, at jeg var bipolar, skyldtes at han ikke kunne få mig ud af mine depressioner. Først diagnosticerede han mig med depression og ADD. Men disse diagnoser var ikke rigtige. Da jeg ikke havde den rette diagnose, fik jeg stadig mine store humørsvingninger og meget angst. Da jeg så blev diagnosticeret med den ’rigtige’ diagnose, bipolar lidelse type 2, føltes det faktisk rigtig godt. En masse ting gav mening. Pludselig kunne jeg se, hvorfor jeg havde følt, som jeg havde hele mit liv.
Jeg tror virkelig, at Monsenso kunne have hjulpet min psykiater med at diagnosticere min lidelse tidligere, fordi app’en hjælper mig med at tracke mit stemningsleje og med at blive mereopmærksom på, hvordan jeg har det. På grund af app’en skal jeg hver dag tage en pause og tænke på, hvordan jeg egentlig har haft det, før jeg taster svaret ind. Når jeg tager til psykiater, kan vi sammen se, hvordan jeg har haft det. En god ting ved app’en er, at mit svar ikke afhænger af min hukommelse, men af hvad jeg faktisk svarede den pågældende dag. At indsamle al den her information kan hjælpe mig, og derved min psykiater, præventativt med at undgå fremtidige depressive eller hypomaniske episoder, fordi vi tydeligt kan identificere, når jeg har humørsvingninger.
I august har min dokumentar, om at være bipolar, premiere på nationalt fjernsyn. Reaktionerne har været overvældende. Rigtig mange personer har skrevet til mig og takket mig for at snakke om sygdommen. Jeg havde oprindeligt tænkt mig, at lave dokumentaren således, at ingen personer ville blive flove over at have sygdommen. Jeg tror, det er lykkedes mig.
Mit håb for fremtiden er, at personer bliver diagnosticeret med lidelsen tidligere end jeg blev. Selvfølgelig kommer det til at afhænge af en masse forskellige faktorer, men jeg tror virkelig, at Monsenso kan gøre en forskel. Mit håb er, at andre psykiatere og patienter også begynder at bruge app’en.
Four years ago, I was diagnosed with bipolar disorder type 2.
For my whole life I had known that something was different about me. I had always struggled with depression and anxiety, and what eventually turned out to be hypomania. When I was 22 I had my first big depression episode and had to start taking anti depressant medications. However, it would take me six more years before I was officially diagnosed with bipolar disorder type 2.
The tricky thing about having the diagnosis of bipolar type 2 is that you are not experiencing the typical manic episode where you are over-energetic and nearly psychotic. Instead, you’re hypomanic, which means that you’re socially well functioning. You’re not psychotic. You actually feel really good. So the problem is that you don’t end up going to your psychiatrist saying that you feel too good. At least I didn’t.
The reason why my psychiatrist found out I was bipolar was because he couldn’t get me out of my depressions. At first, my psychiatrist diagnosed me with depression and ADD. But these diagnoses didn’t fit. When I didn’t have the right diagnosis, I still had my large mood swings, and a lot of anxiety. When I was diagnosed with the ‘right’ diagnosis, of bipolar disorder type 2, it actually felt really nice. A lot of things made sense. Suddenly I could see why I had felt how I had for most of my life.
I really believe that Monsenso could have helped my psychiatrist diagnose my disorder earlier, because the app helps me to keep track of my mood and really helps me to become more aware of how I feel. Due to the app, every single day I have to pause and take a moment to think about how I’ve actually been doing before putting my answers in the app. After doing this, when I go to my psychiatrist we can together see how I’ve actually been. The good thing with the app is that my answer to how I’ve been is not only based on my memory but how I actually answered that day. Logging all of this information has helped my treatment. My psychiatrist and I can better plan how to avoid my future depressive or hypomanic episodes, because we can clearly identify when I am having mood swings.
In August, my documentary about being bipolar aired on national danish television. The reactions have been overwhelming. So many people have messaged me, thanking me for talking about the disease. I had originally made the documentary so that people would not be ashamed about having the disease. I think I have succeed.
My hope for the future is that people will be diagnosed earlier with the disease than me. Of course, that will take a lot of other factors, however I truly believe Monsenso is one of the things that can help. My hope is that other psychiatrists and patients alike will start using the app.
To turn on English subtitles, click on the ‘CC’ at the bottom of the video.
Psychiatrist Kristoffer Södersten from PsykiatriResurs in Sweden shares his experience using the Monsenso mHealth solution.
How does the Monsenso mHealth solution encourage and empower better mental health treatment?
Kristoffer explains how the Monsenso mHealth solution helps him to enhance and inform treatment. Specifically, the solution helps him to gain more relevant information about his patients, such as information that couldn’t have been obtained through the traditional method of verbal sessions. “It’s difficult to retrieve reliable and consistent data from each patient during a verbal consultation with them,” says Kristoffer.
Obtaining the right information is key for psychiatrists and psychologists to provide an accurate diagnosis
“[The accuracy from a diagnosis obtained] from face-to-face consultation depends so much on factors like personal relations, how comfortable the patient is in the conversation, cultural background, etc. Therefore, [due to these factors] it can be very arbitrary about which diagnosis a patient receives. This diagnosis can depend on which clinician he meets, and these other factors.” says Kristoffer. The information gathered from the Monsenso Clinic can help to provide a consistent and clearer view of the patient’s mental health, to better inform a diagnosis.
Kristoffer finds the Monsenso mHealth solution to be particularly helpful in capturing relevant objective data. The solution provides a comprehensive and easily accessible overview of relevant patient data, such as day score, mood score, sleep and medication adherence. Moreover, overview of collected sensor data, such as physical activity, social activity, phone usage and voice features can also be provided. This objective data can help to supplement the subjective data provided during verbal therapy.
“The technology of Monsenso can help us to gather more objective data that – together with the subjective experience – provide a more holistic picture of the patient’s problems, to help provide a more accurate diagnosis and follow-up treatment in a totally different way,” says Kristoffer.
Monsenso mHealth solution is providing a visualization of a historical data, which in some cases can identify why the symptoms appear and help to prevent them.
“You can also use this tool to predict future psychological outcomes, which can help us intervene early and prevent relapse.”
In this video, Monsenso User Peter Hagelund speaks about his experience using our mobile health solution to support his bipolar disorder treatment, and how the solution has helped improve and inform his communication with his psychiatrist.
Prior to using the app, Peter & his psychiatrist followed the typical therapeutic setting, they would meet for an appointment every two-three weeks, and they would have a conversation regarding Peter’s past weeks. Peter would usually say that he had been fine for each appointment, but he would sometimes forget important details regarding his previous weeks that he wanted to discuss.
“It can be pretty tricky to remember, two weeks later [between appointments] how you actually felt that day. With the app it’s really easy to go back and see if your mood has been pretty stable over the last two months, or if you had had some ups and downs over a period,” says Peter Hagelund.
With the app, instead of relying solely on their conversation and Peter’s memory during the appointment, Peter’s psychiatrist can now access his logged data and see how he has been doing, as it is happening. His psychiatrist can view how much he has been sleeping, how much he exercises, how much he drinks, how much anxiety he has, and other relevant aspects to his treatment and his disorder.
“By having the [Monsenso] app, my psychiatrist can actually go into it and see how I’ve been doing, as in, yeah, you say you’ve been doing fine, but I can actually see that you’ve had a bit of ups and a bit of downs, and I think [the app] helps your psychiatrist to get a really honest view of how we, as patients, have been.” says Peter Hagelund.